Syntis Bio’s novel oral therapy, SYNT-101, has achieved a significant milestone in its development, demonstrating excellent tolerability and encouraging efficacy signals in the multiple ascending dose (MAD) segment of its Phase I/Ib SYNTIETY-1 clinical trial. The investigational drug, designed to mimic the metabolic benefits of bariatric surgery through a daily oral tablet, has shown a remarkable ability to influence key satiety and hunger hormones, offering a potential paradigm shift in obesity treatment.
Main Facts
Syntis Bio has announced positive results from the multiple ascending dose (MAD) segment of its Phase I/Ib SYNTIETY-1 trial, evaluating SYNT-101, an oral therapy under development for the potential treatment of obesity. The 28-day study, which enrolled 23 overweight or obese adults, meticulously examined the drug’s safety profile, tolerability, and its impact on metabolic markers and weight loss across three distinct dose groups. Notably, SYNT-101 was well-tolerated at all administered dose levels, ranging from 857mg to 2,571mg, with no participants requiring dose reductions or withdrawing from the study due to adverse events. Gastrointestinal side effects were reported at rates comparable to those observed in the placebo group, underscoring the therapy’s favorable safety profile.
Furthermore, exploratory pharmacodynamic assessments revealed a significant and dose-dependent impact of SYNT-101 on key hormones regulating appetite and satiety. Participants receiving SYNT-101 experienced substantial increases in glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), hormones known to promote feelings of fullness, and a marked reduction in ghrelin, often referred to as the "hunger hormone." These hormonal changes were found to be comparable in magnitude to those observed following bariatric surgery, a gold standard for significant and sustained weight loss.
The trial also reported positive weight loss outcomes, with SYNT-101 recipients in all three dose groups exhibiting greater weight loss compared to those who received a placebo. The observed weight loss was described as being similar in scale to that achieved with current GLP-1 receptor agonist therapies over a comparable treatment duration. These findings collectively represent a significant de-risking milestone for SYNT-101 and provide a robust foundation for its progression into Phase II clinical development.
Chronology of Development
The journey of SYNT-101 from concept to promising clinical candidate has been marked by strategic development and rigorous evaluation. Syntis Bio initiated the SYNTIETY-1 Phase I/Ib trial in March 2026, a crucial step in assessing the safety, tolerability, and initial efficacy of its investigational once-daily oral pill designed to combat obesity. This initial phase was designed to provide early insights into how the drug behaves in the human body and its potential therapeutic effects.
The trial was meticulously structured to include both single ascending dose (SAD) and multiple ascending dose (MAD) segments. The SAD arm, which preceded the MAD segment, provided initial data on the drug’s safety and pharmacokinetic profile at single doses. Results from this earlier SAD arm were reported in July 2026, further informing the design and expectations for the subsequent MAD study.
The recently announced MAD segment, which involved 23 overweight or obese adults, was specifically designed to evaluate the effects of repeated daily administration of SYNT-101 over a 28-day period. This extended dosing period allowed researchers to assess the drug’s sustained tolerability, its cumulative impact on metabolic markers, and to gather more robust data on weight loss outcomes. The successful completion of the MAD segment, with its overwhelmingly positive safety and efficacy signals, marks a pivotal moment in the development of SYNT-101, paving the way for more extensive investigations in larger patient populations.
Supporting Data: A Deep Dive into SYNT-101’s Mechanism and Impact
The efficacy of SYNT-101 appears to be rooted in its unique mechanism of action, which targets the gut’s local environment rather than relying on systemic circulation. The drug is designed to form a temporary, localized lining in the duodenum, the first part of the small intestine. This physical barrier is theorized to interact with ingested food, triggering satiety responses as a direct consequence of this interaction. This localized action is a key differentiator, potentially offering a distinct advantage in terms of side effect profiles and overall patient experience compared to systemically acting drugs.
The exploratory pharmacodynamic data from the MAD segment provides compelling evidence for SYNT-101’s impact on hormonal regulation. The observed two-to-five-fold increases in GLP-1 and PYY are particularly significant. GLP-1 is a potent incretin hormone that slows gastric emptying, enhances insulin secretion, and suppresses glucagon release, all of which contribute to reduced food intake and improved glycemic control. PYY, another satiety hormone, also plays a crucial role in signaling fullness to the brain. The concurrent reduction in ghrelin levels further supports the drug’s ability to mitigate hunger signals.
The comparison of these hormonal changes to those observed after gastric bypass surgery is particularly noteworthy. Bariatric surgery, while highly effective for weight loss, is an invasive procedure with significant risks and is not suitable for all patients. The ability of an oral therapy to elicit similar hormonal shifts suggests that SYNT-101 could offer a less invasive and more accessible alternative for achieving profound metabolic improvements.
The weight loss data, showing greater weight reduction in SYNT-101 recipients compared to placebo, further validates the drug’s therapeutic potential. The reported similarity in weight loss to that seen with GLP-1 therapies over a comparable period is a critical benchmark, given the established efficacy of these agents in the obesity market. This suggests that SYNT-101 may offer a comparable or even superior therapeutic profile, potentially with a different safety and tolerability profile due to its localized mechanism.
The study’s design, involving a 28-day treatment period and three distinct dose levels (857mg, 1,714mg, and 2,571mg), allowed for a thorough assessment of dose-response relationships. The consistent tolerability across all these escalating doses, without any participant withdrawals or dose adjustments, is a strong indicator of the drug’s safety margin. The fact that gastrointestinal adverse events were no more frequent than in the placebo group is a significant positive finding, as gastrointestinal side effects are a common challenge with many obesity medications.
Official Responses: Syntis Bio’s Perspective on the Promising Results
David Rosenbaum, Chief Development Officer at Syntis Bio, expressed considerable optimism regarding the trial results. "SYNT-101 was designed to produce a specific multi-hormone signature, one that mimics the metabolic response of bariatric surgery but via a once-daily oral tablet," Rosenbaum stated. This statement underscores the company’s strategic intent and the scientific rationale behind SYNT-101’s development. The goal has been to translate the profound metabolic benefits of a surgical intervention into a convenient, non-invasive oral therapy.
Rosenbaum further elaborated on the significance of the findings, highlighting the continued demonstration of tolerability across all dose cohorts. "The continued demonstration of tolerability across all dose cohorts, together with encouraging efficacy signals, reinforce the potential of a therapy that, unlike GLP-1s and other obesity drug candidates, is specifically designed to avoid systemic circulation." This emphasis on avoiding systemic circulation points to a potential key advantage of SYNT-101, suggesting a possible reduction in systemic side effects that can be associated with other obesity medications. By acting locally in the gut, SYNT-101 may offer a more targeted and potentially safer approach.
Looking ahead, Rosenbaum characterized the current data as a "significant de-risking milestone." He added, "Overall, these data mark a significant de-risking milestone for SYNT-101 and provide a strong foundation for its advancement into Phase II." This statement clearly communicates the company’s confidence in the drug’s prospects and its preparedness to move to the next stage of clinical development, which will involve larger patient populations and more extensive efficacy assessments. The successful completion of Phase I/Ib trials is crucial for investor confidence and for securing the resources needed for further development.
Implications for the Future of Obesity Treatment
The promising results of SYNT-101’s Phase I/Ib trial carry significant implications for the future landscape of obesity treatment. The growing global obesity epidemic continues to drive demand for safe, effective, and accessible therapeutic options. Current treatments, while valuable, often come with limitations, including side effect profiles, cost, and the need for long-term adherence.
SYNT-101’s unique mechanism of action, targeting local gut responses to mimic bariatric surgery effects without systemic circulation, offers a potentially novel approach. If its efficacy and safety profile are further validated in larger trials, it could represent a paradigm shift in how obesity is managed.
Potential for a Differentiated Therapeutic Option: The localized action of SYNT-101 could translate into a differentiated safety profile compared to systemically acting drugs, potentially appealing to patients who have experienced or are concerned about systemic side effects. The ability to achieve hormonal changes comparable to bariatric surgery via an oral tablet could position SYNT-101 as a highly attractive option for individuals seeking significant weight loss and metabolic improvement without the risks associated with surgery.
Broadening Treatment Accessibility: An oral therapy that effectively addresses obesity could significantly broaden treatment accessibility. Oral medications are generally easier to administer, less intimidating for patients, and potentially more cost-effective to produce and distribute than injectable therapies or surgical interventions. This could make effective obesity management available to a wider segment of the population.
Complementary or Alternative to Existing Therapies: Depending on its long-term efficacy and safety profile, SYNT-101 could serve as a valuable alternative or even a complementary therapy to existing treatments like GLP-1 receptor agonists. The distinct mechanism might offer benefits for patients who do not respond optimally to current therapies or who experience intolerable side effects.
Future Research and Development: The positive outcomes from the MAD segment of the SYNTIETY-1 trial are a strong impetus for Syntis Bio to advance SYNT-101 into Phase II. These larger trials will be critical for confirming the observed efficacy in terms of weight loss and metabolic improvements, further characterizing the safety profile in a broader patient population, and exploring optimal dosing regimens. The company’s strategic focus on mimicking bariatric surgery outcomes through an oral tablet is a bold ambition, and these early results suggest that SYNT-101 has the potential to be a significant contender in the evolving field of obesity therapeutics. The success of SYNT-101 could redefine expectations for oral treatments in managing this complex chronic disease.
About the Author
